NRXS — Neuraxis Income Statement
0.000.00%
Last trade - 00:00- $19.42m
- $17.51m
- $2.69m
Annual income statement for Neuraxis, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.93 | 2.72 | 2.68 | 2.46 | 2.69 |
| Cost of Revenue | |||||
| Gross Profit | 1.45 | 2.25 | 2.39 | 2.16 | 2.32 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 5.83 | 5.69 | 6.06 | 12.8 | 9.84 |
| Operating Profit | -3.9 | -2.97 | -3.37 | -10.3 | -7.16 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.73 | -3.03 | -4.78 | -14.6 | -8.24 |
| Net Income After Taxes | -3.73 | -3.03 | -4.78 | -14.6 | -8.24 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.73 | -3.03 | -4.78 | -14.6 | -8.24 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.32 | -3.78 | -5.54 | -14.6 | -8.45 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.742 | -0.618 | -0.908 | -3.38 | -1.22 |
| Dividends per Share |